274 related articles for article (PubMed ID: 23007264)
1. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials.
Komócsi A; Vorobcsuk A; Kehl D; Aradi D
Arch Intern Med; 2012 Nov; 172(20):1537-45. PubMed ID: 23007264
[TBL] [Abstract][Full Text] [Related]
2. Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials.
Villablanca PA; Holmes D; Mohananey D; Briceno DF; Núñez Gil IJ; Kargoli F; Gupta T; Kizer JR; Bortnick AE; Wiley J; Menegus MA; Pyo R; García M; Ramakrishna H; Mookadam F
Coron Artery Dis; 2017 Aug; 28(5):395-405. PubMed ID: 28328784
[TBL] [Abstract][Full Text] [Related]
3. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Weitz JI
Thromb Haemost; 2014 Nov; 112(5):924-31. PubMed ID: 25030773
[TBL] [Abstract][Full Text] [Related]
4. Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Obonska K; Navarese EP; Lansky A; Tarantini G; Rossini R; Kozinski M; Musumeci G; Di Pasquale G; Górny B; Szczesniak A; Kowalewski M; Gurbel PA; Kubica J
Atherosclerosis; 2013 Aug; 229(2):482-8. PubMed ID: 23672879
[TBL] [Abstract][Full Text] [Related]
5. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
Ganetsky VS; Hadley DE; Thomas TF
Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
[TBL] [Abstract][Full Text] [Related]
6. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
Oldgren J; Wallentin L; Alexander JH; James S; Jönelid B; Steg G; Sundström J
Eur Heart J; 2013 Jun; 34(22):1670-80. PubMed ID: 23470494
[TBL] [Abstract][Full Text] [Related]
7. Risk and benefit of direct oral anticoagulants or PAR-1 antagonists in addition to antiplatelet therapy in patients with acute coronary syndrome.
Gao F; Shen H; Wang ZJ; Yang SW; Liu XL; Zhou YJ
Thromb Res; 2015 Aug; 136(2):243-9. PubMed ID: 26037286
[TBL] [Abstract][Full Text] [Related]
8. Novel oral anticoagulants in acute coronary syndrome.
Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
[TBL] [Abstract][Full Text] [Related]
9. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
Krantz MJ; Kaul S
J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
[TBL] [Abstract][Full Text] [Related]
11. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome: A Systematic Review of Randomized Controlled Trials.
Sharma A; Lavie CJ; Sharma SK; Garg A; Vallakati A; Mukherjee D; Marmur JD
Mayo Clin Proc; 2016 Aug; 91(8):1084-93. PubMed ID: 27492914
[TBL] [Abstract][Full Text] [Related]
12. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis.
Chiarito M; Cao D; Cannata F; Godino C; Lodigiani C; Ferrante G; Lopes RD; Alexander JH; Reimers B; Condorelli G; Stefanini GG
JAMA Cardiol; 2018 Mar; 3(3):234-241. PubMed ID: 29417147
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cardiovascular events after acute coronary syndrome.
Wallentin L
Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
[TBL] [Abstract][Full Text] [Related]
15. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials.
Fu L; Zhu W; Huang L; Hu J; Ma J; Lip GYH; Hong K
Am J Cardiovasc Drugs; 2019 Feb; 19(1):37-47. PubMed ID: 30182350
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy and anticoagulation in patients with hypertension.
Griffin G
Am Fam Physician; 2005 Mar; 71(5):897-9. PubMed ID: 15768617
[TBL] [Abstract][Full Text] [Related]
18. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Gibson CM; Chakrabarti AK; Mega J; Bode C; Bassand JP; Verheugt FW; Bhatt DL; Goto S; Cohen M; Mohanavelu S; Burton P; Stone G; Braunwald E;
J Am Coll Cardiol; 2013 Jul; 62(4):286-90. PubMed ID: 23602776
[TBL] [Abstract][Full Text] [Related]
19. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Bittl JA; Baber U; Bradley SM; Wijeysundera DN
J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
[TBL] [Abstract][Full Text] [Related]
20. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
